The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Ras mediates cell proliferation, survival and differentiation. Mutations in K-Ras4B are predominant at residues G12, G13 and Q61. Even though all impair GAP-assisted GTP → GDP hydrolysis, the mutation frequencies of K-Ras4B in human cancers vary. Here we aim to figure out their mechanisms and differential oncogenicity. In total, we performed 6.4 μs molecular dynamics simulations on the wild-type K-Ras4B (K-Ras4B WT-GTP/GDP) catalytic domain, the K-Ras4B WT-GTP–GAP complex, and the mutants (K-Ras4B G12C/G12D/G12V-GTP/GDP, K-Ras4B G13D-GTP/GDP, K-Ras4B Q61H-GTP/GDP) and their complexes with GAP. In addition, we simulated ‘exchanged’ nucleotide states. These comprehensive simulations reveal that in solution K-Ras4B WT-GTP exists in two, active and inactive, conformations. Oncogenic mutations differentially elicit an inactive-to-active conformational transition in K-Ras4B-GTP; in K-Ras4B G12C/G12D-GDP they expose the bound nucleotide which facilitates the GDP-to-GTP exchange. These mechanisms may help elucidate the differential mutational statistics in K-Ras4B-driven cancers. Exchanged nucleotide simulations reveal that the conformational transition is more accessible in the GTP-to-GDP than in the GDP-to-GTP exchange. Importantly, GAP not only donates its R789 arginine finger, but stabilizes the catalytically-competent conformation and pre-organizes catalytic residue Q61; mutations disturb the R789/Q61 organization, impairing GAP-mediated GTP hydrolysis. Together, our simulations help provide a mechanistic explanation of key mutational events in one of the most oncogenic proteins in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent mutant forms were KRASG12D (41%), KRASG12V (28%), and KRASG12C (14%).49”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations in G12, G13, or Q61 residue in the active site can lock KRAS in the GTP-bound form by impeding the hydrolysis to GDP catalyzed by GAPs, thus keeping downstream signaling constitutively active [16, 17].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [16]
In the citing paper
“The total simulation times of these studies were in the range of 1–8 μs, which is reasonable but likely not sufficient to unravel long-time dynamics associated with slow conformational changes.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of simple potential functions for simulating liquid water
Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983) · The Journal of Chemical Physics · doi:10.1063/1.445869 · Cited by 41,298
Particle mesh Ewald: An N ⋅log( N ) method for Ewald sums in large systems
Darden, T., York, D., & Pedersen, L. (1993) · The Journal of Chemical Physics · doi:10.1063/1.464397 · Cited by 30,546
Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977) · Journal of Computational Physics · doi:10.1016/0021-9991(77)90098-5 · Cited by 21,239
The Amber biomolecular simulation programs
Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20290 · Cited by 9,535
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Regulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
Cited by
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Hereditary breast and ovarian cancer: new genes in confined pathways
Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.72 · Cited by 367
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320
The current understanding of KRAS protein structure and dynamics
Pantsar, T. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.12.004 · Cited by 282
“demonstrated that discrepancy among the mutants in their dynamics exist [27,100,103], especially in regions located in the effector protein binding interface, but these subtle differences and their biological consequences are still not properly understood.”
BackgroundThe KRAS-G12C inhibitor: activity and resistance
Liu, J., Kang, R., & Tang, D. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00383-9 · Cited by 219
Ras and Rap1: A tale of two GTPases
Shah, S., Brock, E. J., Ji, K., & Mattingly, R. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 211
“For example, studies have already aimed to determine the differences in the oncogenicity of KRas4B mutations [43].”
BackgroundDrugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Self-citationChen, J., Zhang, S., Wang, W., Pang, L., Zhang, Q., & Liu, X. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01470 · Cited by 141
Nussinov, R., Jang, H., Tsai, C.-J., & Cheng, F. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006658 · Cited by 130
Self-citationKRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis
Rabara, D., Tran, T. H., Dharmaiah, S., Stephens, R. M., McCormick, F., Simanshu, D. K., & Holderfield, M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908353116 · Cited by 128
“Discussion KRAS residues G12, G13, and Q61 are all important for coordinating GTP binding, and mutation at these residues has been suggested to disrupt GAP-stimulated GTP hydrolysis and constitutively activate the RAF/MAPK pathway (28).”
BackgroundOncogenic Ras Isoforms Signaling Specificity at the Membrane
Nussinov, R., Tsai, C.-J., & Jang, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2727 · Cited by 122
“Thus, the most populated state of KRas differs from that of the KRas mutant (45, 46); and the most populated state of KRas4B at the membrane differs from that of NRas because they favor altered interactions with membrane phospholipids (14, 24, 37).”
BackgroundSelf-citationK-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology
Sakamoto, K., Kamada, Y., Sameshima, T., Yaguchi, M., Niida, A., Sasaki, S., Miwa, M., Ohkubo, S., Sakamoto, J.-I., Kamaura, M., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.147 · Cited by 118
Protein conformational ensembles in function: roles and mechanisms
Nussinov, R., Liu, Y., Zhang, W., & Jang, H. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00114h · Cited by 136
Self-citationDeconstruction of the Ras switching cycle through saturation mutagenesis
Bandaru, P., Shah, N. H., Bhattacharyya, M., Barton, J. P., Kondo, Y., Cofsky, J. C., Gee, C. L., Chakraborty, A. K., Kortemme, T., Ranganathan, R., et al. (2017) · eLife · doi:10.7554/elife.27810 · Cited by 117
“dynamics analysis of the effects of oncogenic mutations in K-Ras (Lu et al., 2016).”
BackgroundInfluentialNi, D., Lu, S., & Zhang, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21585 · Cited by 116
Self-citationTherapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
Poole, A., Karuppiah, V., Hartt, A., Haidar, J. N., Moureau, S., Dobrzycki, T., Hayes, C., Rowley, C., Dias, J., Harper, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32811-1 · Cited by 110
Dynamic regulation of RAS and RAS signaling
Kölch, W., Berta, D., & Rosta, E. (2023) · Biochemical Journal · doi:10.1042/bcj20220234 · Cited by 104
Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2505783 · Cited by 90
Deactivation Pathway of Ras GTPase Underlies Conformational Substates as Targets for Drug Design
Lu, S., Ni, D., Wang, C., He, X., Lin, H., Wang, Z., & Zhang, J. (2019) · ACS Catalysis · doi:10.1021/acscatal.9b02556 · Cited by 93
Self-citationOncogenic G12D mutation alters local conformations and dynamics of K-Ras
Vatansever, S., Erman, B., & Gumus, Z. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-48029-z · Cited by 96
Pantsar, T., Rissanen, S., Dauch, D., Laitinen, T., Vattulainen, I., & Poso, A. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006458 · Cited by 85
Chen, J., Wang, J., Yang, W., Zhao, L., & Hu, G. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01174 · Cited by 84
KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
Pereira, F. D. S., Ferreira, A. I., Reis, C. A., Sousa, M. J., Oliveira, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11030398 · Cited by 81
Li, S., Jang, H., Zhang, J., & Nussinov, R. (2018) · Structure · doi:10.1016/j.str.2018.01.011 · Cited by 79
“…a small p21 guanosine triphosphatase (GTPase), Ras plays a central role in cellular signal transduction pathways (Lacal et al., 1986; Lu et al., 2016a; Malumbres and Barbacid, 2003), including proliferation, differentiation, apoptosis, and senescence (Quinlan and Settleman, 2009;…”
BackgroundMethodSelf-citationGupta, P., Mohammad, T., Dahiya, R., Roy, S., Noman, O. M., Alajmi, M. F., Hussain, A., & Hassan, M. I. (2019) · Scientific Reports · doi:10.1038/s41598-019-55199-3 · Cited by 76
Drugging K-RasG12C through covalent inhibitors: Mission possible?
Ni, D., Li, X., He, X., Zhang, H., Zhang, J., & Lu, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.007 · Cited by 73
Self-citationGTP Hydrolysis Without an Active Site Base: A Unifying Mechanism for Ras and Related GTPases
Calixto, A. R., Moreira, C., Pabis, A., Kötting, C., Gerwert, K. B., Rudack, T., & Kamerlin, S. C. L. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b03193 · Cited by 72
McGrath, J. S., Honrado, C., Moore, J. H., Adair, S. J., Varhue, W. B., Salahi, A., Farmehini, V., Goudreau, B. J., Nagdas, S., Blais, E. M., et al. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.12.033 · Cited by 68
“While a significant majority of PDAC patients (~95%) exhibit KRAS mutations [6] that activate oncogenic proteins [7], tumorigenicity cannot be assessed solely based on specific mutations.”
BackgroundVatansever, S., Erman, B., & Gumus, Z. H. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.04.003 · Cited by 69
“For atomistic level comparative analyses, studies have utilized MD simulations to focus on the differences in the global dynamics of active and/or inactive K-Ras mutants [22,23].”
BackgroundWang, Y., Ji, D., Lei, C., Chen, Y., Qiu, Y., Li, X., Li, M., Ni, D., Pu, J., Zhang, J., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.044 · Cited by 67
“Several studies on the structural mechanism of GAP-accelerated GTP hydrolysis concluded that GAP stabilizes the ‘correct’ arrangement of the catalytic Q61 of K-Ras4B and activates hydrolysis via its ‘arginine finger’ R789 [17,63,64].”
BackgroundSelf-citationThe mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane
Jang, H., Smith, I. N., Eng, C., & Nussinov, R. (2021) · iScience · doi:10.1016/j.isci.2021.102438 · Cited by 66
Self-citationThe principle of conformational signaling
Tompa, P. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00011h · Cited by 66
Parker, J. A., & Mattos, C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031427 · Cited by 61
“However, targeting the protein–protein interaction (PPI) interface on Ras, which includes both dynamic switch I and switch II regions and is large and relatively flat, presents challenges for traditional small molecules (Lu et al. 2016b).”
BackgroundThe effects of mutant Ras proteins on the cell signalome
Takács, T., Kudlik, G., Kurilla, A., Szeder, B., Buday, L., & Vas, V. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09912-8 · Cited by 62
Ragotte, R. J., Dhanrajani, A. D., Pleydell-Pearce, J., Bel, K. L. D., Tarailo‐Graovac, M., van Karnebeek, C., Terry, J., Senger, C., McKinnon, M. L., Seear, M. D., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2016.12.006 · Cited by 61
The road to ERK activation: Do neurons take alternate routes?
Zobon, N. T. M., & Blackwell, K. T. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109541 · Cited by 61
The quaternary assembly of KRas4B with Raf-1 at the membrane
Jang, H., Zhang, M., & Nussinov, R. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.018 · Cited by 57
Self-citationPrecision medicine review: rare driver mutations and their biophysical classification
Nussinov, R., Jang, H., Tsai, C., & Cheng, F. (2019) · Biophysical Reviews · doi:10.1007/s12551-018-0496-2 · Cited by 57
“Simulations can also reveal mutations that can deactivate an essential enzymatic action which makes the enzyme switch back into the inactive state, as in the case of Ras oncogenic mutations, e.g., Q61L and G12 mutations (Lu et al. 2016a, b; Pantsar et al. 2018).”
BackgroundSelf-citationK-RasG12D Has a Potential Allosteric Small Molecule Binding Site
Feng, H., Zhang, Y., Bos, P. H., Chambers, J. M., Dupont, M. M., & Stockwell, B. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01300 · Cited by 57
Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation
Murphy, B., Terrell, E. M., Chirasani, V. R., Weiss, T. J., Lew, R. E., Holderbaum, A. M., Dhakal, A., Posada, V., Fort, M., Bodnar, M. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30881-9 · Cited by 53
Structural impact of GTP binding on downstream KRAS signaling
Menyhárd, D. K., Pálfy, G., Orgován, Z., Vida, I., Keserű, G. M., & Perczel, A. (2020) · Chemical Science · doi:10.1039/d0sc03441j · Cited by 58
Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma
Kulkarni, P., Leite, V. B. P., Roy, S., Bhattacharyya, S., Mohanty, A. R., Achuthan, S., Singh, D., Appadurai, R., Rangarajan, G., Weninger, K., et al. (2022) · Biophysics Reviews · doi:10.1063/5.0080512 · Cited by 51
Chen, J., Wang, L., Wang, W., Sun, H., Pang, L., & Bao, H. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104639 · Cited by 49
Proactive and reactive roles of TGF-β in cancer
Kuburich, N. A., Sabapathy, T., Demestichas, B. R., Maddela, J. J., den Hollander, P., & Mani, S. A. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.08.002 · Cited by 49
Jang, H., Banerjee, A., Chavan, T., Gaponenko, V., & Nussinov, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.785063 · Cited by 43
Self-citationShalaeva, D. N., Cherepanov, D. A., Galperin, M. Y., Golovin, A. V., & Mulkidjanian, A. Y. (2018) · eLife · doi:10.7554/elife.37373 · Cited by 40
Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B
Li, X., Dai, J., Ni, D., He, X., Zhang, H., Zhang, J., Fu, Q., Liu, Y., & Lu, S. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.020 · Cited by 42
Self-citationChen, J., Zeng, Q., Wang, W., Hu, Q., & Bao, H. (2022) · RSC Advances · doi:10.1039/d1ra07936k · Cited by 40
Intrinsic GTPase activity of K-RAS monitored by native mass spectrometry
Moghadamchargari, Z., Huddleston, J., Shirzadeh, M., Zheng, X., Clemmer, D. E., M. Raushel, F., Russell, D. H., & Laganowsky, A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00532 · Cited by 38
Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants
Moghadamchargari, Z., Shirzadeh, M., Liu, C., Schrecke, S., Packianathan, C., Russell, D. H., Zhao, M., & Laganowsky, A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022403118 · Cited by 38
Halder, S., Parte, S. C., Kshirsagar, P., Muniyan, S., Nair, H. B., Batra, S. K., & Seshacharyulu, P. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188737 · Cited by 43
Real-Time In-Cell NMR Reveals the Intracellular Modulation of GTP-Bound Levels of RAS
Zhao, Q., Fujimiya, R., Kubo, S., Marshall, C. B., Ikura, M., Shimada, I., & Nishida, N. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108074 · Cited by 39
Zhang, H., Ni, D., Fan, J., Li, M.-Y., Zhang, J., Chen, H., Nussinov, R., & Lu, S. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00591 · Cited by 37
Self-citationA New View of Activating Mutations in Cancer
Nussinov, R., Tsai, C., & Jang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2125 · Cited by 38
“In line with expectation, despite the global similarity among the crystal structures of the mutant proteins and wild-type Ras (106), their populated conformations vary (107, 108).”
BackgroundSelf-citationLi, Y., Zhang, Y., Großerüschkamp, F., Stephan, S., Cui, Q., Kötting, C., Xia, F., & Gerwert, K. (2018) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.8b00342 · Cited by 36
The Structural Basis of the Farnesylated and Methylated KRas4B Interaction with Calmodulin
Jang, H., Banerjee, A., Marcus, K., Makowski, L., Mattos, C., Gaponenko, V., & Nussinov, R. (2019) · Structure · doi:10.1016/j.str.2019.08.009 · Cited by 35
“Our simulations closely followed the same protocol as in our previous works (Chavan et al., 2015; Jang et al., 2015; Jang et al., 2017; Jang et al., 2016a; Jang et al., 2016b; Liao et al., 2018; Lu et al., 2015; Lu et al., 2016; Muratcioglu et al., 2017; Ozdemir et al., 2018a; 2018b; Zhang et al., 2017; Zhang et al.,…”
MethodSelf-citationA Sos proteomimetic as a pan-Ras inhibitor
Hong, S. H., Yoo, D. Y., Conway, L. P., Richards-Corke, K. C., Parker, C. G., & Arora, P. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101027118 · Cited by 36
“where RT is the total concentration of H-Ras (1-166), LST is the total concentration of fluorescence peptide, and FSB is the fraction of bound fluorescence peptide.”
BackgroundNeurodevelopmental disorders, immunity, and cancer are connected
Nussinov, R., Tsai, C., & Jang, H. (2022) · iScience · doi:10.1016/j.isci.2022.104492 · Cited by 37
“Small GTPases of the Ras superfamily are key regulators of diverse cellular and developmental events including differentiation, cell division, vesicle transport, nuclear assembly, and control of the cytoskeleton (Lundquist, 2006).”
Self-citationNussinov, R. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169044 · Cited by 41
Self-citationAllosteric KRas4B Can Modulate SOS1 Fast and Slow Ras Activation Cycles
Liao, T.-J., Jang, H., Fushman, D., & Nussinov, R. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.07.016 · Cited by 36
“638 Biophysical Journal 115, 629–641, August 21, 2018 Oncogenic KRas4B mutants in the GTP-bound state (KRas4B-GTP) present a conformation with tightly closed switch I and II regions, whereas the GDP-bound mutants have large fluctuations in both switch regions, showing more widely open nucleotide-binding sites than wil…”
BackgroundSelf-citationKumar, S. U., Bithia, R., Kumar, D. T., Doss, C. G. P., & Zayed, H. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1830177 · Cited by 36
“As the oncogenic mutations in K-Ras are documented to cause an inactive-to-active conformational transition, our research focused on understanding the dynamics of the active-GTPbound state of wild type and mutant K-Ras proteins (Lu et al., 2016; Rom an et al., 2018).”
BackgroundAn integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
Wang, H., Lv, Q., Xu, Y., Cai, Z., Zheng, J., Cheng, X., Dai, Y., Janne, P. A., Ambrogio, C., & Köhler, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.012 · Cited by 36
Mehaffey, M. R., Schardon, C. L., Novelli, E. T., Cammarata, M. B., Webb, L. J., Fast, W. L., & Brodbelt, J. S. (2019) · Chemical Science · doi:10.1039/c9sc01032g · Cited by 31
Ni, D., Song, K., Zhang, J., & Lu, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112249 · Cited by 29
Self-citationMcFall, T. B., & Stites, E. C. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110096 · Cited by 31
“These possibilities could be investigated with a variety of methods (Hunter et al., 2015; Lu et al., 2016; Rabara et al., 2019).”
Conformational Dynamics Allows Sampling of an “Active-like” State by Oncogenic K-Ras-GDP
Grudzien, P. K., Jang, H., Leschinsky, N., Nussinov, R., & Gaponenko, V. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167695 · Cited by 31
Self-citationKumawat, A., Chakrabarty, S., & Kulkarni, K. A. (2017) · Scientific Reports · doi:10.1038/srep45829 · Cited by 30
PDEδ Binding to Ras Isoforms Provides a Route to Proper Membrane Localization
Muratcioğlu, S., Jang, H., Gürsoy, A., Keskin, Ö., & Nussinov, R. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b03035 · Cited by 31
Self-citationMaking NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
Vilachã, J. F., Mitchel, S. C., Akele, M. Z., Evans, S., & Groves, M. R. (2020) · Crystals · doi:10.3390/cryst10090725 · Cited by 30
Insight into human Miro1/2 domain organization based on the structure of its N-terminal GTPase
Smith, K. P., Focia, P. J., Chakravarthy, S., Landahl, E. C., Klosowiak, J. L., Rice, S. E., & Freymann, D. M. (2019) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107656 · Cited by 31
“In Ras, the corresponding mutation disrupts the catalytic interactions of the cognate GTPase activating protein (RasGAP) [86,87] thereby limiting stimulation of GTP hydrolysis and, as a second order effect, stabilizing the ‘active’ GTP-bound state.”
BackgroundOncogenic mutations on Rac1 affect global intrinsic dynamics underlying GTP and PAK1 binding
Acuner, S. E., Sumbul, F., Torun, H., & Haliloǧlu, T. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.01.016 · Cited by 33
Lokhandwala, J., Smalley, T. B., & Tran, T. H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394702 · Cited by 29
“The side chain of G12D, in any given rotameric conformation, prevents the key arginine fi nger of GAP from inserting into the active site of RAS to participate in the transition-state coordination of the GAP-mediated GTP hydrolysis reaction (6, 40 – 42).”
BackgroundA CRISPR-Cas9 repressor for epigenetic silencing of KRAS
Liu, J., Sun, M., Cho, K. B., Gao, X., & Guo, B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105304 · Cited by 30
Structure of an inactive conformation of GTP-bound RhoA GTPase
Lin, Y., Lu, S., Zhang, J., & Zheng, Y. (2021) · Structure · doi:10.1016/j.str.2020.12.015 · Cited by 29
Self-citationHafezi, S., Saber-Ayad, M. M., & Abdel‐Rahman, W. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910219 · Cited by 28
“G12 mutation is followed by that of G13 (9%) and Q61 (1%) in PDAC [23].”
BackgroundComputer-Aided Drug Design Boosts RAS Inhibitor Discovery
Wang, G., Bai, Y., Cui, J., Zong, Z., Gao, Y., & Zheng, Z. (2022) · Molecules · doi:10.3390/molecules27175710 · Cited by 29
“KRASG12C could rompt the exposure of the effector binding site and the nucleotide binding site, which can increase the intrinsic GTPase activity and thus upregulate signal transduction [28,29].”
BackgroundMolecular dynamics simulations for the structure-based drug design: targeting small-GTPases proteins
Parise, A., Cresca, S., & Magistrato, A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2387856 · Cited by 28
Active and Inactive Cdc42 Differ in Their Insert Region Conformational Dynamics
Haspel, N., Jang, H., & Nussinov, R. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.12.007 · Cited by 27
“This has been shown to be the case in K-Ras4B as well (48).”
BackgroundMethodResultInfluentialSelf-citationUnderstand KRAS and the Quest for Anti-Cancer Drugs
Han, C. W., Jeong, M. S., & Jang, S. B. (2021) · Cells · doi:10.3390/cells10040842 · Cited by 29
“Recent studies hav focused on attempts to block nucleotide exchange [8,9].”
BackgroundA saturation-mutagenesis analysis of the interplay between stability and activation in Ras
Hidalgo, F., Nocka, L. M., Shah, N. H., Gorday, K., Latorraca, N. R., Bandaru, P., Templeton, S., Lee, D., Karandur, D., Pelton, J. G., et al. (2022) · eLife · doi:10.7554/elife.76595 · Cited by 28
“Furthermore, the catalytic activity impairment produced by Gln 61 (Hunter et al., 2015; Lu et al., 2016) renders the GAP ineffective and the mutational sensitivity of the Ras+GAP condition looks identical to the unregulated condition.”
BackgroundHead perturbations during walking while viewing a head-fixed target.
Das, V. E., Zivotofsky, A. Z., DiScenna, A. O., & Leigh, R. J. (1995) · PubMed · Cited by 30
Ni, D., Liu, D., Zhang, J., & Lu, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010151 · Cited by 26
“Mutation rate of K-Ras4B in PDAC can be as high as 95% [5,16,17] and accumulating evidence suggests that both calmodulin (CaM) and phosphatidylinositide-3 kinase (PI3Kα) play key roles in the K-Ras4B-driven adenocarcinoma [18–21].”
BackgroundSelf-citationHu, Z., & Martí, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213865 · Cited by 25
RAS‐targeted cancer therapy: Advances in drugging specific mutations
Liu, C., Ye, D., Yang, H., Chen, X., Su, Z., Li, X., Ding, M., & Liu, Y. (2023) · MedComm · doi:10.1002/mco2.285 · Cited by 30
The dynamic mechanism of RASSF5 and MST kinase activation by Ras
Liao, T.-J., Jang, H., Tsai, C., Fushman, D., & Nussinov, R. (2017) · Physical Chemistry Chemical Physics · doi:10.1039/c6cp08596b · Cited by 26
Self-citationOncogenic KRas mobility in the membrane and signaling response
Nussinov, R., Tsai, C., & Jang, H. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.009 · Cited by 25
Self-citationDe novo ARF3 variants cause neurodevelopmental disorder with brain abnormality
Sakamoto, M., Sasaki, K., Sugie, A., Nitta, Y., Kimura, T., Gürsoy, S., Çinleti, T., Iai, M., Sengoku, T., Ogata, K., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab224 · Cited by 27
Zeng, J., Weng, J., Zhang, Y., Xia, F., Cui, Q., & Xu, X. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c04679 · Cited by 24
Klimpel, A., Stillger, K., Wiederstein, J. L., Krüger, M., & Neundorf, I. (2020) · FEBS Journal · doi:10.1111/febs.15612 · Cited by 26
Wang, X. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00844 · Cited by 23
Zhuang, H., Fan, J., Li, M., Zhang, H., Yang, X., Lin, L., Lu, S., Wang, Q., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.915512 · Cited by 23
“KRAS mutations are dominated by single-base missense mutations, and 98% of which are found at three mutation hotspots: G12, G13, and Q61 (6, 9).”
BackgroundSelf-citationKarami, Y., Bitard‐Feildel, T., Laine, É., & Carbone, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-34508-2 · Cited by 26
Small molecule combats cancer-causing KRAS protein at last
Herbst, R. S., & Schlessinger, J. (2019) · Nature · doi:10.1038/d41586-019-03242-8 · Cited by 25
KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma
Than, M. T., O’Hara, M. H., Stanger, B. Z., & Reiss, K. A. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0519 · Cited by 23
Normal Mode Analysis of KRas4B Reveals Partner Specific Dynamics
Eren, M., Tunçbağ, N., Jang, H., Nussinov, R., Gürsoy, A., & Keskin, Ö. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00891 · Cited by 22
Self-citationTumour-agnostic kinase inhibitors
Adashek, J. J., Nikanjam, M., & Kurzrock, R. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01147-y · Cited by 21
“In human cancers, most KRAS mutations are KRAS G12 mutations 110 .”
Xiong, Y., Zeng, J., Xia, F., Cui, Q., Deng, X., & Xu, X. (2022) · Journal of Computational Chemistry · doi:10.1002/jcc.26846 · Cited by 20
Mahran, R., Kapp, J. N., Valtonen, S., Champagne, A., Ning, J., Gillette, W., Stephen, A. G., Hao, F., Plückthun, A., Härmä, H., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00315 · Cited by 23
KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2K–MAPK1 inhibition
Janardhan, H. P., Meng, X., Dresser, K., Hutchinson, L., & Trivedi, C. M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192205 · Cited by 22
“These data and previous literature reports suggest structural, biochemical, and functional similarities among KRAS G12/13 and BRAF V600 mutations (Yao et al., 2015; Smith et al., 2013; Lu et al., 2016; Hunter et al., 2015; Hobbs et al., 2016; Hobbs and Der, 2019).”
BackgroundResult
Metadata
- Authors
- Lu, S., Jang, H., Nussinov, R., & Zhang, J.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Frederick National Laboratory for Cancer Research (US)
- Tel Aviv University (IL)
- Corresponding author
- Nussinov, Ruth
- Zhang, Jian
- Venue
- Scientific Reports
- Published
- 2016-02-23
- Volume
- 6
- Issue
- 1
- Pages
- 21949-21949
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4763299
- OpenAlex
- W2282990014
- Cited by
- 219
- References
- 69
- Citations by year
- 2026: 13 · 2025: 33 · 2024: 20 · 2023: 23 · 2022: 25 · 2021: 22 · 2020: 23 · 2019: 26 · 2018: 15 · 2017: 13 · 2016: 5
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (HHSN261200800001E)
- Frederick National Laboratory for Cancer Research (HHSN261200800001E.)
- National Natural Science Foundation of China (81302698, 973 Program, HHSN261200800001E, 81473137, 2015CB910403, 81322046)
- Shanghai Rising-Star Program (13QA1402300)
- National Institutes of Health (#HHSN261200800001E, HHSN261200800001C)
- Program for New Century Excellent Talents in University (NCET-12-0355)
- National Key Research and Development Program of China (2015CB910403)
- National Cancer Institute (HHSN261200800001E))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- K-Ras4B, oncogenic Ras mutations, G12D, G12V, small GTPases, GTP hydrolysis, GDP/GTP exchange, conformational change, GTPase-activating protein, RAS-driven cancers, molecular dynamics simulation
- MeSH terms
- Amino Acid Sequence, Arginine, Glutamine, Glycine, Guanosine Diphosphate, Guanosine Triphosphate, Humans, Hydrolysis, Mutation, Neoplasm Proteins, Gene Expression, Proto-Oncogene Proteins p21(ras), Protein Structure, Secondary, Catalytic Domain, Biocatalysis, Molecular Dynamics Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.